Aptorum Group Ltd
NASDAQ:APM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aptorum Group Ltd
Net Issuance of Common Stock
Aptorum Group Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aptorum Group Ltd
NASDAQ:APM
|
Net Issuance of Common Stock
$5.1m
|
CAGR 3-Years
210%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Issuance of Common Stock
£12.4m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Net Issuance of Common Stock
$140.7m
|
CAGR 3-Years
413%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Net Issuance of Common Stock
£58.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
82%
|
|
|
Niox Group PLC
LSE:NIOX
|
Net Issuance of Common Stock
£100k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-55%
|
|
Aptorum Group Ltd
Glance View
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.
See Also
What is Aptorum Group Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
5.1m
USD
Based on the financial report for Dec 31, 2025, Aptorum Group Ltd's Net Issuance of Common Stock amounts to 5.1m USD.
What is Aptorum Group Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-22%
The average annual Net Issuance of Common Stock growth rates for Aptorum Group Ltd have been 210% over the past three years , -22% over the past five years .
